Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Grit Bio Closes $60 Million Round for Tumor-Infiltrating Lymphocyte Oncology Drugs

publication date: Sep 8, 2023

Shanghai Grit Biotechnology, a cell therapy company, raised more than $60 million in a Series B financing round to develop its pipeline of drugs based on Tumor-Infiltrating lymphocytes. The company’s lead drug, GT101, has started a pivotal Phase II trial for solid tumor cancers. TIL uses lymphoctyes (T cells and B cells) derived from a tumor biopsy, expands them, and infuses the cells back into the patient. Unlike CAR-T therapies, TIL candidates naturally target the tumor, and they typically attack multiple targets in the tumor. The B Round was led by CICC. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here